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Dear Editor, 
Wogonin (5, 7-Dihydroxy-8-methoxy flavone) is a traditional naturally occurring flavo-
noid derived from the root extract of Chinese medicine, named Scutellaria baicalensis 
Georgi. Wogonin contains various biological properties which include allergic diseases, anti-
cancer therapy, and anti-inflammatory activities. Wogonin also shows the effects of removing 
toxins and cleansing the heart (Ancuceanu et al., 2019). The anticancer therapeutic activity of 
wogonin has been shown by the regulation of different cell signaling pathways, which in-
cludes protein kinase B pathway (serine-threonine kinase) and AMP-activated protein kinase 
pathways (Bei et al., 2020). Wogonin also shows positive therapeutic anticancer effects in 
breast cancer by inhibiting the 5‑LO/BLT2/ERK/IL‑8/MMP‑9 signaling cascade and estab-
lishes a major pharmacological anticancer activity (Bibi et al., 2019). Current biological and 
pharmacological updates on wogonin have been reviewed (Table 1). 
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Table 1: Current biological and pharmacological updates on wogonin 
Key findings Reference 
In osteoarthritis, wogonin shows its therapeutic effects by inhibiting IL-1β-induced 
gene expression of MMP-1, MMP-13, and ADAMTS-4, and also restores the gene 
expression of type II collagen that has been inhibited by IL-1β. 
Du et al., 2019 
Wogonin attaches to chondrocytes DNA through an intercalation mechanism. It 
was set up to be limited in the nucleus and exhibit protective effects in osteoarthri-
tis chondrocytes by inducing the anti-apoptotic proteins. Wogonin suppresses the 
IL-1β mediated induction of ROS, DNA fragmentation and also extrinsic and in-
trinsic apoptotic pathways. 
Ewendt and 
Foller, 2019 
Wogonin and its homologous compounds reserved the viabilities of human hepa-
toma cells accompanying the loss of MMP and the exhaustion of glutathione con-
tent preferentially induced apoptosis through the intrinsic pathways in human he-
patoma (HepG2) cells by the measurement of the representative indexes of apop-
tosis and the control of overexpression of Bcl-2.  On the other hand, wogonin is 
not involved in the growth of embryonic hepatic L02 cells at lower concentrations 
but induces slight apoptosis at high concentration (200 mM). It shows that wogon-
in preferentially kills tumor cells. 
Fang et al., 
2019 
The anticancer mechanism of wogonin has been recognized by modulation of var-
ious cell signaling pathways, which include serine-threonine kinase Akt (protein 
kinase B) and AMP-activated protein kinase (AMPK) pathways and inhibition of te-
lomere activity. Also, wogonin decreases DNA adduct formation with a carcino-
genic compound 2-Aminofluorene and inhibits the growth of drug-resistant malig-
nant cells and their movement and metastasis, without any side effects. In recent 
times, newly synthesized wogonin derivatives have been identified with notable 
anti-tumor activity. 
Gao et al., 
2019 
In recent research, it was found that wogonin suppresses the LPS-enhanced in-
vasiveness and metastasis of breast cancer cell lines by showing an inhibitory ef-
fect on the lipopolysaccharide (LPS)-enhanced invasiveness of MDA‑MB‑231 
cells. Wogonin also inhibits the synthesis of matrix metallopeptidase‑9 (MMP‑9) 
and interleukin‑8 (IL‑8), which makes it critical to promote invasiveness in MDA‑
MB‑231 cells.  
Gharari et al., 
2020 
Wogonin shows renoprotective effects for cisplatin-based anticancer therapy. In a 
recent study it was found that wogonin substantially decreased the increased lev-
els of serum creatinine and blood urea nitrogen (BUN) nearly to the normal level. 
It effectively inhibited RIPK1 by occupying the ATP-binding pocket of the enzyme, 
which is a type of regulator of necroptosis. Shockingly, wogonin improved the anti-
proliferative outcome of cisplatin on human hepatoma HepG2 cells. As a result, 
wogonin may be used in cisplatin-based anticancer therapy as a renoprotective 
adjuvant.  
Hanioka et al., 
2020 
Wogonin shows anti-inflammatory activity by inhibiting hyperpermeability, expres-
sion of CAMs, and also adhesion and migration of leukocytes, thereby endorsing 
its usefulness as a therapy for vascular inflammatory diseases.  
Hong et al., 
2020 
Wogonin reduces glycolysis and cell proliferation in cancer cells expressing wild-
type p53 but not mutated p53. It also increases the expression of p53 and p53-
inducible glycolysis and apoptosis regulator (TIGAR), while decreases glucose 
transporter 1 (GLUT1) and some key glycolytic enzymes.  Expressing wild-type 
and mutant-type p53 in HCT116 p53-/-cells proved that the inhibitory outcome of 
wogonin on glycolysis in cancer cells is reliant on wild type p53. All these findings 
make clear the broad anti-tumor effect of wogonin and suggest a novel possibility 
for the therapeutic approach in cancer. The effect of wogonin on glucose uptake, 
lactate generation, and ATP content is assessing in hepatocellular, colon and 
ovarian cancer cells. 
Huang et al., 
2020 
Wogonin can ease liver fibrosis via regulating the activation and apoptosis of he-
patic stellate cells, and possibly an efficient drug to treat and prevent liver fibrosis. 
Wogonin can largely increase cle-caspase3, cle-caspase9 expression and the ra-
tio of Bax/Bcl-2 in T6 cells.  
Jiang et al., 
2019 
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Key findings Reference 
Wogonin shows its anti-inflammatory and chondroprotective potential by inducing 
mild oxidative stress throughout the generation of ROS and reduction of cellular 
GSH and modulating the cellular redox leading to the initiation of Nrf2/ARE path-
ways during activation of ROS/ERK/Nrf2/HO-1-SOD2-NQO1-GCLC signaling axis 
in OA chondrocytes.  
Jiao et al., 
2019 
Roles of wogonin in metabolism associated enzymes in human gastric cancer and 
lung adenocarcinoma cells show its various antitumor mechanisms. Various met-
abolic regulatory mechanisms shown by wogonin in different tumor tissues should 
be considered in antitumor therapy. With a combination of wogonin and certain 
enzyme inhibitors in energy, metabolism may stop the supply of energy to tumor 
cells and therefore helps in inhibition of tumor cell proliferation. Wogonin affects 
the energy metabolism and the acidic microenvironment in SGC-7901 cells by de-
creasing HIF-1α and MCT-4 expressions. In A549 cells, wogonin has no signifi-
cant property on the energy metabolism, representing that the strong inhibitory ef-
fect of wogonin on cell proliferation may be induced by another mechanism, but 
not by the inhibition of the energy metabolism. 
Khan and 
Kamal, 2019a 
Drug interactions between wogonin and docetaxel in rats with mammary tumors 
indicated a linear pharmacokinetic profile of wogonin after oral administration. Ad-
ditionally, the combined use of wogonin and docetaxel resulted in a major in-
crease in both of their in vivo exposure, this may increase not only therapeutic but 
also toxic effects. As a result, the alterations of pharmacokinetics should be taken 
into concern when wogonin and docetaxel are co-administered. 
Khan and 
Kamal, 2019b 
Wogonin is used as a therapeutic agent for treating AR (Allergic Rhinitis), it shows 
the pharmacological activity by decreasing the infiltration of eosinophils and levels 
of T-helper type 2 cytokines.  
Khushdil et al., 
2019 
Wogonin shows a potent anti-influenza activity mediated by regulation of AMPK 
activation, signifying that wogonin has the potential to be developed as an anti-
influenza drug. In the comparison of wogonin treatment after influenza, infection 
led to the up-regulation of interferon (IFN)-induced antiviral signal. Besides this, 
influenza virus infection in A549 cells induced 5' adenosine monophosphate-
activated protein kinase (AMPK), phosphorylation and activation in a time-
dependent approach and wogonin treatment led to the suppression of phosphory-
lation.  
Kim et al., 
2019 
Wogonin may reduce melanin synthesis by declining tyrosinase activity via the 
ER-ERK pathway. Western blot analysis also discovered that wogonin significant-
ly inhibits the protein expression levels of TYR and JNK in A375 cells, which was 
inverted by ICI182780. Diminishing the protein expression levels of TYR and JNK 
may be associated with the regulation of melanin synthesis. RT-PCR shows that 
wogonin extensively inhibited mRNA expression levels of TYR, TRP-1, ERK2, 
JNK2, TRP-2 and ERK1, which may be concerned in the regulation of melanin 
synthesis.  
Kong et al., 
2019 
Wogonin repairs the lipotoxicity-induced decline of peroxisome proliferator-
activated receptor α (PPARα) and adiponectin receptor 2 (AdipoR2) in hepato-
cytes, both in vivo and in vitro. Reduction of PPARα abolishes the defensive effect 
of wogonin on NCTC 1469 cells, also including the up-regulation of AdipoR2. It 
shows that wogonin may be a potential therapeutic agent for NAFLD via the up-
regulation of hepatic PPARα/AdipoR2. 
Liang et al., 
2019 
Wogonin decreases the appearance of TCF-1, TCF-3, and LEF-1 and reserves 
nuclear accumulation of b-catenin as well as the binding of b-catenin and TCF-1, 
TCF-3, or LEF-1. All this shows that wogonin might inhibit the expression of 
VEGF, which is an important factor regulated by b-catenin. By taking together, 
wogonin may act as a potent inhibitor of Wnt/b-catenin and influence vascular 
permeability, and also provides new therapeutics in certain diseases.  
Liau et al., 
2019 
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Key findings Reference 
The SDs (solid dispersions) of wogonin had an advanced solubility than the physi-
cal mixtures. Based on XRD (X-ray diffraction) and DSC (differential scanning cal-
orimetry), wogonin was transformed from a crystalline morphology to an amor-
phous structure. The considerably increased solubility of SDs and the additional 
preparation of arginine solution could notably increase the bioavailability of 
wogonin. 
Luo et al., 
2019 
Wogonin inhibits the activation of the TLR4/NF-κB pathway, which results in the 
inflammatory response and also protects human retinal pigment epithelium cells 
by LPS-induced barrier dysfunction. Many studies have confirmed that wogonin 
acts as a strong inhibitor of several other kinases involved in signal transduction.  
Oomen et al., 
2020 
Wogonin suppressed hyperglycemia, improved cardiac function, and mitigated 
cardiac fibrosis in STZ-induced diabetic mice. It also attenuates diabetic-induced 
cardiomyocyte apoptosis and necrosis. Wogonin treatment shows the properties 
of anti-oxidative stress and anti-inflammation. Wogonin potentially eases hyper-
glycemia associated cardiomyocyte impairment through inhibiting inflammation 
and oxidative stress. 
Tan et al., 
2019 
Wogonin has neuroprotective effects on amyloid-ߚ peptides- (Aߚ-) induced toxici-
ty. By taking wogonin orally it enhances the performance and also activates the 
neurite outgrowth of (Alzheimer’s disease) AD cells by increasing neurite length 
and complexity of Tet-On Aߚ42-GFP SH-SY5Y neuroblastoma cells (AD cells). It 
shows that wogonin might be a promising multifunctional drug for AD. 
Wang and Cui, 
2019 
Wogonin decreases the restoration ability of CSC (cancer stem cells) by inhibiting 
the formation and sinking the size of spheres. Wogonin at a concentration of 40–
80 μM successfully minimizes potential risk from CSC. Taken together, this con-
firmed a new approach of wogonin for increasing a possible therapy for osteosar-
coma. 
Wang et al., 
2019a 
Wogonin shows activity against the hepatitis B virus, HBV DNA levels are attenu-
ated wogonin therapy. These effects have lately confirmed in HepG2.2.15 cell 
lines. At the same time, wogonin harms HBeAg secretion. Wogonin has an inhibi-
tory outcome on the production of HBsAg. Wogonin also appears to be of ad-
vantage in the supervision of “nonalcoholic fatty liver disease”. Wogonin exhibits 
several of hepatoprotective properties. 
Wang et al., 
2019b 
TF (Tissue factor) promoter activity of Wognin has been seen by inhibition of 
ERK/Egr-1- and JNK/AP-1-mediated transactivation of leading to downregulation 
of TF expression and this activity is induced by inflammatory mediators.  
Wang et al., 
2019a 
Wogonin shows anti-oxidant activity, which possibly shows anti-inflammatory, anti-
cancer, and antiviral and neuroprotective actions. Anxiolytic activity of Wogonin 
suggests a new mechanism of action, which includes interaction with the benzodi-
azepine (BZD) binding site of the GABAA receptor. While the safety record of 
wogonin is extraordinary and huge literature about its pharmacological effects is 
available while it has not been used in Western medicine as a pure chemical. 
Wang et al., 
2020 
Wogonin can inhibit the growth of tumor cells, stimulate apoptosis, and restrain 
angiogenesis. The molecular mechanisms involve reactive oxygen species, Ca2+, 
tumor necrosis factor-related apoptosis-inducing ligand, tumor necrosis factor-
alpha, and NF-κB. Additionally, the synergistic effect of wogonin with 5-
fluorouracil, etoposide, and adriamycin to develop chemotherapy and reverse drug 
resistance has also been established.  
Xing et al., 
2019a 
Wogonin shows its anticancer activity by producing the major reduction in the G1 
cell-cycle regulatory proteins cyclin D1, 4 along with overexpression of cell-cycle 
inhibitory proteins p27 and cyclin-dependent kinase 2. Besides, the flavone con-
siderably diminished the phosphorylated level of protein kinase B (AKT), and 
maintenance of low-catenin expression level was dependent on glycogen syn-
thase kinase 3 activation at Ser9 in glioblastoma cells. 
Xing et al., 
2019b 
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Key findings Reference 
Clinical impact of wogonin on the management of ovarian cancer results in in-
creased expressions of Bax and p53 and down-regulated protein levels of estro-
gen receptor alpha (ER-ߙ), VEGF, and Bcl-2. Wogonin augmented caspase-3 
cleavage and induced apoptosis in A2780 cells. MPP, a specific ER-ߙ inhibitor, 
notably enhanced antitumor effects of wogonin in A2780 cells. 
Zhang et al., 
2019 
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